Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2019-08-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-019-02378-wPMID 31444607PMCID PMC11028183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

  2019cited by this paper
• Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

  2019cited by this paper
• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

  2018cited by this paper
• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

  2018cited by this paper
• Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

  2018cited by this paper
• The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• New developments in the management of head and neck cancer – impact of pembrolizumab

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• Properdin: A multifaceted molecule involved in inflammation and diseases.

  2018cited by this paper
• Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

  2018cited by this paper
• PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma

  2017cited by this paper
• The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

  2017cited by this paper
• Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis

  2017cited by this paper
• PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

  2017cited by this paper
• Immunotherapy in head and neck cancer: aiming at EXTREME precision

  2017cited by this paper
• Epacadostat Shows Value in Two SCCHN Trials.

  2017cited by this paper
• Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

  2017cited by this paper
• TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

  2017cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

  2016cited by this paper
• Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

  2016cited by this paper
• Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

  2016cited by this paper
• Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  2016cited by this paper
• Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

  2016cited by this paper
• Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma

  2016cited by this paper
• The head and neck cancer immune landscape and its immunotherapeutic implications.

  2016cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma

  2015cited by this paper
• Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

  2015cited by this paper
• Robust enumeration of cell subsets from tissue expression profiles

  2015cited by this paper
• Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma

  2015cited by this paper
• Epidemiology of head and neck cancer.

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• Epidemiologic trends in head and neck cancer and aids in diagnosis.

  2014cited by this paper
• An updated overview of HPV-associated head and neck carcinomas

  2014cited by this paper
• CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.

  2013cited by this paper
• Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer

  2013cited by this paper
• Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer

  2012cited by this paper
• The molecular biology of head and neck cancer

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Immune therapy for cancer.

  2009cited by this paper
• Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.

  2009cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

  2005cited by this paper

• Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma

  2025influential citation
• The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma

  2024cites this paper
• The prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

  2024cites this paper
• Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer

  2024cites this paper
• CCDC71L as a novel prognostic marker and immunotherapy target via lipid metabolism in head and neck squamous cell carcinoma.

  2024cites this paper
• Seven Immune-Related Genes' Prognostic Value and Correlation with Treatment Outcome in Head and Neck Squamous Cell Carcinoma

  2023cites this paper
• Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

  2023cites this paper
• Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity

  2023influential citation
• CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome

  2022cites this paper
• Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

  2022cites this paper
• Understanding the tumor microenvironment in head and neck squamous cell carcinoma

  2022cites this paper
• Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies

  2021cites this paper
• Digital pathology for the identification of prognostic biomarkers in head and neck cancer

  2021cites this paper
• Integrated Analysis Reveals ENDOU as a Biomarker in Head and Neck Squamous Cell Carcinoma Progression

  2021cites this paper
• Biomarkers for immunotherapy response in head and neck cancer.

  2020cites this paper
• Immune checkpoint expression in HNSCC patients before and after definitive chemoradiotherapy

  2020cites this paper
• The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma

  2020cites this paper